1
|
Ameayou S, Ouali M, Hassoune S, Ben Abdelaziz A, Bousfiha AA. Student's attitudes towards medical education in Arabic (Morocco 2020). Tunis Med 2023; 101:26-35. [PMID: 37682257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Indexed: 09/09/2023]
Abstract
INTRODUCTION Several studies suggest that teaching medicine in the national language is essential for quality training and for communication with patients. AIM AND METHODS To measure the students' level of understanding of their French language training and skills acquisition, as well as the difficulties they encounter in communicating with patients and their families, and the extent to which they accept medical studies in Arabic, we conducted a descriptive crosssectional study on a random sample of 450 students from the Faculty of Medicine and Pharmacy of Casablanca. RESULTS 16% of the students had trouble assimilating their lessons in French, 48.9% of them had trouble communicating with the patient, and 22% were ready to study medicine in Arabic. Regarding the effect of teaching medicine in Arabic on different fields, 42.2% of the students mentioned a positive effect on the training, 85.2% on the communication with the patient during their training on field and 64.8% on the quality of care. CONCLUSION Our study revealed the existence of multiple difficulties among students, particularly in the field of communication with the patient, which is a fundamental pillar for the quality of health care, hence the need to provide effective and rapid solutions to the problem of language in medical education.
Collapse
Affiliation(s)
- Sana Ameayou
- م مختبر علم األوبئة، كلية الطب والصيدلة بالدار البيضاء، جامعة الحسن الثاني بالدار البيضاء، المغرب
| | - Meriem Ouali
- ك لية الطب والصيدلة بالدار البيضاء، جامعة الحسن الثاني بالدار البيضاء، المغرب
| | - Samira Hassoune
- م مختبر علم األوبئة، كلية الطب والصيدلة بالدار البيضاء، جامعة الحسن الثاني بالدار البيضاء، المغرب م.3 مختبر علم األمراض الخلوية والجزيئية / وبائيات وأنسجة األمراض المزمنة والسرطانية، جامعة الحسن الثاني بالدار البيضاء، المغرب
| | | | - Ahmed Aziz Bousfiha
- م قسم طب األطفال لألمراض التعفنية والمناعة السريرية بمستشفى ابن رشد التعليمي، جامعة الحسن الثاني بالدار البيضاء، المغرب م./ مختبر المناعة السريرية وااللتهاب واألرجية، كلية الطب والصيدلة بالدار البيضاء، جامعة الحسن الثاني بالدار البيضاء، المغرب
| |
Collapse
|
2
|
Boutakioute B, Zouine Y, Chehboun A, Ouali M, El Ganouni NCI. Corrigendum to ‘Successful preoperative embolization of a cystic-solid variant of cerebellopontine angle hemangioblastoma’ [Radiology Case Reports 17 (2022) 4799-4803]. Radiol Case Rep 2022; 18:421. [DOI: 10.1016/j.radcr.2022.10.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
3
|
van Akkooi A, Hauschild A, Long G, Mandala M, Kicinski M, Govaerts AS, Klauck I, Ouali M, Lorigan P, Eggermont A. 464TiP Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
|
4
|
Boutakioute B, Benzalim M, Chehboun A, Ouali M, Ganouni NCIE. Spontaneous external jugular vein pseudoaneurysm: A rare cause of neck swelling. Radiol Case Rep 2022; 17:4790-4794. [PMID: 36238217 PMCID: PMC9550843 DOI: 10.1016/j.radcr.2022.09.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Revised: 08/31/2022] [Accepted: 09/07/2022] [Indexed: 11/07/2022] Open
Abstract
Pseudoaneurysm of the external jugular vein is a relatively unusual cause of a neck mass caused by the low pressure venous system. Regardless of etiology, spontaneous pseudoaneurysms are extremely rare, and only few cases have been described in literature. They require surgery; however, most patients can be safely discharged with close follow-up with a vascular surgeon. This case demonstrates a 30-year-old man who presented with a non-tender, compressible, left-sided neck mass that enlarged with Valsalva, and intermittent paresthesias. Ultrasound confirmed a cystic mass of unknown etiology containing doppler flow suggesting the diagnosis of an external jugular vein pseudoaneurysm, confirmed by a CT angiogrphy. The patient refused the surgery, and we agreed he was safe for discharge at that time and could follow up with vascular surgery as an outpatient.
Collapse
Affiliation(s)
- Badr Boutakioute
- Department of Radiology, Ar-Razi Hospital, Med VI University Hospital Center, Marrakech 40000, Morocco
- Corresponding author.
| | - Meriam Benzalim
- Department of Radiology, Ibn Tofail Hospital, Med VI University Hospital Center, Marrakech 40000, Morocco
| | - Anass Chehboun
- Department of Radiology, Ar-Razi Hospital, Med VI University Hospital Center, Marrakech 40000, Morocco
| | - Meriem Ouali
- Department of Radiology, Ar-Razi Hospital, Med VI University Hospital Center, Marrakech 40000, Morocco
| | | |
Collapse
|
5
|
Boutakioute B, Zouine Y, Chehboun A, Ouali M, Ganouni NCIE. Successful preoperative embolization of a cystic-solid variant of cerebellopontine angle hemangioblastoma. Radiol Case Rep 2022; 17:4799-4803. [PMID: 36212759 PMCID: PMC9535285 DOI: 10.1016/j.radcr.2022.09.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Revised: 09/09/2022] [Accepted: 09/13/2022] [Indexed: 11/01/2022] Open
Abstract
Tumors of the cerebellopontine angle (CPA) represent an heterogeneous group which can arise extradural, intradural-extraaxial or intraaxial compartment. Hemangioblastomas of the cerebellopontine angle (CPA) are extremely rare. Computed tomography (CT) and magnetic resonance imaging (MRI) are often the gold-standard radiological imaging modalities used in characterizing the lesion's features, and its relationship with the surrounding structures. They are vascular lesions and may cause profuse bleeding intraoperatively, that is why angiography remains a crucial diagnostic and therapeutic tool, by reducing both the presurgical differential diagnosis, as well as the intraoperative bleeding by providing capability of embolization of this vascular tumor. We present the case of a 65 year old patient with a cystic-solid variety of HMB at the right CPA, which was successfully treated by a combination of an endovascular preoperative embolization and surgery without major complications or neurological deficits.
Collapse
|
6
|
Belarbi S, Bensemmane SD, Bouguerra I, Ouali M, Makri-Mokrane S. Démence du sujet jeune révélant un syndrome de CACH. Rev Neurol (Paris) 2021. [DOI: 10.1016/j.neurol.2021.02.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
7
|
El Mortaji H, Elghazi M, Belhadj Z, Boutakioute B, Ouali M, Cherif Idrissi Ganouni N. Aneurysmal bone cyst of the ethmoid on fibrous dysplasia: A usual association within a rare location. Radiol Case Rep 2019; 14:1356-1359. [PMID: 31516652 PMCID: PMC6734539 DOI: 10.1016/j.radcr.2019.07.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Accepted: 07/29/2019] [Indexed: 11/16/2022] Open
Abstract
Aneurysmal bone cyst is a non-neoplastic lesion consisting of blood filled sinusoidal spaces that expand from the affected bone. The most common locations of aneurysmal bone cysts are the metaphysis of long bones, followed by flat bones. Only 2% of all are found in the head and neck area, with mandible and maxilla being the most frequent sites involved, involvement of the ethmoidal bone is extremely rare. Their occurrence on a pre-existing bone lesion is described. Imaging features may assist in diagnosis by demonstrating blood-fluid levels, which are a characteristic finding in these lesions. We present computed tomography and magnetic resonance imaging findings of aneurysmal bone cyst of the ethmoid sinus on fibrous dysplasia in a 12-year-old female.
Collapse
|
8
|
Liu Z, Ouali M, Coulibaly S, Clerc MG, Taki M, Tlidi M. Characterization of spatiotemporal chaos in a Kerr optical frequency comb and in all fiber cavities. Opt Lett 2017; 42:1063-1066. [PMID: 28295092 DOI: 10.1364/ol.42.001063] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Complex spatiotemporal dynamics have been a subject of recent experimental investigations in optical frequency comb microresonators and in driven fiber cavities with Kerr-type media. We show that this complex behavior has a spatiotemporal chaotic nature. We determine numerically the Lyapunov spectra, allowing us to characterize different dynamical behavior occurring in these simple devices. The Yorke-Kaplan dimension is used as an order parameter to characterize the bifurcation diagram. We identify a wide regime of parameters where the system exhibits a coexistence between the spatiotemporal chaos, the oscillatory localized structure, and the homogeneous steady state. The destabilization of an oscillatory localized state through radiation of counter-propagating fronts between the homogeneous and the spatiotemporal chaotic states is analyzed. To characterize better the spatiotemporal chaos, we estimate the front speed as a function of the pump intensity.
Collapse
|
9
|
Ouali M, Coulibaly S, Taki M, Tlidi M. Extended and localized Hopf-Turing mixed-mode in non-instantaneous Kerr cavities. Opt Express 2017; 25:4714-4719. [PMID: 28380742 DOI: 10.1364/oe.25.004714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
We investigate the spatio-temporal dynamics of a ring cavity filled with a non-instantaneous Kerr medium and driven by a coherent injected beam. We show the existence of a stable mixed-mode solution that can be either extended or localized in space. The mixed-mode solutions are obtained in a regime where Turing instability (often called modulational instability) interacts with self-pulsing phenomenon (Andronov-Hopf bifurcation). We numerically describe the transition from stationary inhomogeneous solutions to a branch of mixed-mode solutions. We characterize this transition by constructing the bifurcation diagram associated with these solutions. Finally, we show stable localized mixed-mode solutions, which consist of time-periodic oscillations that are localized in space.
Collapse
|
10
|
Bessieres S, Ouali M, Lanaspèze C, Vieillevigne L. 38. Use of flattening filter free beams for stereotactic body radiotherapy treatments: Impact of the size of the planning target volume. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.11.090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
11
|
Vieillevigne L, Bessieres S, Ouali M, Lanaspeze C. EP-1710: Use of FFF beams for SBRT treatments: impact of the size of the PTV? Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32961-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Khalifa J, Ouali M, Chaltiel L, Le Guellec S, Le Cesne A, Blay JY, Cousin P, Chaigneau L, Bompas E, Piperno-Neumann S, Bui-Nguyen B, Rios M, Delord JP, Penel N, Chevreau C. Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. BMC Cancer 2015; 15:700. [PMID: 26472661 PMCID: PMC4608145 DOI: 10.1186/s12885-015-1697-8] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2014] [Accepted: 10/07/2015] [Indexed: 12/25/2022] Open
Abstract
Background Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe the activity of trabectedin in a retrospective, multi-center French series of patients with SFTs. Methods Patients were mainly identified through the French RetrospectYon database and were treated between January 2008 and May 2013. Trabectedin was administered at an initial dose of 1.5 mg/m2, q3 weeks. The best tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors 1.1. The Kaplan–Meier method was used to estimate median progression-free survival (PFS) and overall survival (OS). The growth-modulation index (GMI) was defined as the ratio between the time to progression with trabectedin (TTPn) and the TTP with the immediately prior line of treatment (TTPn-1). Results Eleven patients treated with trabectedin for advanced SFT were identified. Trabectedin had been used as second-line treatment in 8 patients (72.7 %) and as at least third-line therapy in a further 3 (27.3 %). The best RECIST response was a partial response (PR) in one patient (9.1 %) and stable disease (SD) in eight patients (72.7 %). Disease-control rate (DCR = PR + SD) was 81.8 %. After a median follow-up of 29.2 months, the median PFS was 11.6 months (95 % CI = 2.0; 15.2 months) and the median OS was 22.3 months (95 % CI = 9.1 months; not reached). The median GMI was 1.49 (range: 0.11–4.12). Conclusion Trabectedin is a very promising treatment for advanced SFTs. Further investigations are needed.
Collapse
Affiliation(s)
- J Khalifa
- Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.
| | - M Ouali
- Department of Statistics, Institut Claudius Regaud / Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irène Joliot-Curie, 31059, Toulouse, France.
| | - L Chaltiel
- Department of Statistics, Institut Claudius Regaud / Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irène Joliot-Curie, 31059, Toulouse, France.
| | - S Le Guellec
- Department of Pathology, Institut Claudius Regaud / Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irène Joliot-Curie, 31059, Toulouse, France.
| | - A Le Cesne
- Department of Medical Oncology, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France.
| | - J-Y Blay
- Department of Medical Oncology, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008, Lyon, France.
| | - P Cousin
- Department of Medical Oncology, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008, Lyon, France.
| | - L Chaigneau
- Department of Medical Oncology, Jean Minjoz University Hospital, 3 Boulevard Alexandre Fleming, 25030, Besançon, France.
| | - E Bompas
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Site Hospitalier Nord Boulevard Jacques Monod, 44805, Saint-Herblain, France.
| | - S Piperno-Neumann
- Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75248, Paris, France.
| | - B Bui-Nguyen
- Department of Medical Oncology, Institut Bergonié, 229 cours de l'Argonne, 33000, Bordeaux, France.
| | - M Rios
- Department of Medical Oncology, Centre Alexis Vautrin, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.
| | - J-P Delord
- Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.
| | - N Penel
- Department of Medical Oncology, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.
| | - C Chevreau
- Department of Medical Oncology, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse - Oncopôle, 1, avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.
| |
Collapse
|
13
|
Ravaud A, Oudard S, De Fromont M, Chevreau C, Gravis G, Zanetta S, Theodore C, Jimenez M, Sevin E, Laguerre B, Rolland F, Ouali M, Culine S, Escudier B. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. Ann Oncol 2015; 26:1123-1128. [PMID: 25802238 DOI: 10.1093/annonc/mdv149] [Citation(s) in RCA: 107] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2014] [Accepted: 03/12/2015] [Indexed: 08/08/2023] Open
Abstract
BACKGROUND Papillary renal cell carcinoma (PRCC), type 1 and type 2, represents 10%-15% of renal cell carcinomas (RCC). There is no standard first-line treatment of metastatic PRCC (mPRCC). Anti-angiogenics have shown activity in retrospective studies but no prospective studies in pure papillary histology have been reported, but one with foretinib. PATIENTS AND METHODS A prospective phase II study evaluated sunitinib in first-line treatment of mPRCC. The primary end point was overall response rate (ORR). Secondary end points were progression-free survival (PFS) and overall survival (OS). RESULTS Fifteen and 46 patients, respectively, with type 1 and type 2 mPRCC were enrolled. Using the MSKCC scoring system: 12 (20%), 33 (55%) and 9 (15%) patients were, respectively, in the favourable, intermediate or poor risk group and 7 undetermined. Median follow-up is 51.4 months. In type 1, 2 patients 13% [95% confidence interval (CI) 0.1-30.5] had a partial response (PR), 10 had stable disease (SD) with 5 (33%) ≥12 weeks. In type 2, 5 patients 11% (95% CI 1.9-20.3) had a PR, 25 had SD with 10(22%) ≥12 weeks. Median PFS was 6.6 months (95% CI 2.8-14.8) in type 1 and 5.5 months (95% CI 3.8-7.1) in type 2. Median OS was 17.8 (95% CI 5.7-26.1) and 12.4 (95% CI 8.2-14.3) months, respectively, in type 1 and 2. Safety was as expected with sunitinib for metastatic RCC. CONCLUSION Sunitinib showed activity in treatment of type 1 and 2 mPRCC but lower than in clear-cell mRCC. Both PFS and OS are longer in type I PRCC. Sunitinib represents an acceptable option in first-line treatment of mPRCC.
Collapse
Affiliation(s)
- A Ravaud
- Department of Medical Oncology, Bordeaux University Hospital, Bordeaux.
| | - S Oudard
- Department of Medical Oncology, Paris Rene Descartes University, Paris
| | | | - C Chevreau
- Department of Medical Oncology, Institut Claudius Régaud/Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse
| | - G Gravis
- Department of Medical Oncology, Institut Paoli Calmettes, Marseille
| | - S Zanetta
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon
| | - C Theodore
- Department of Medical Oncology, Hôpital Foch, Suresnes
| | - M Jimenez
- Research and Development Department, Unicancer, Paris
| | - E Sevin
- Department of Medical Oncology, Centre François Baclesse, Caen
| | - B Laguerre
- Department of Medical Oncology, Centre Eugène Marquis, Rennes
| | - F Rolland
- Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Nantes
| | - M Ouali
- Department of Biostatistics, Institut Claudius Régaud/Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse
| | - S Culine
- Medical Oncology, Hôpital Saint-Louis, Paris
| | - B Escudier
- Department of Medical Oncology, Gustave Roussy, Villejuif, France
| |
Collapse
|
14
|
Beauval JB, Roumiguié M, Ouali M, Doumerc N, Thoulouzan M, Mazerolles C, Rischmann P, Malavaud B, Soulié M. [A prospective trial comparing consecutive series of open retropubic and robot-assisted laparoscopic radical prostatectomy in a centre: Oncologic and functional outcomes]. Prog Urol 2015; 25:370-8. [PMID: 25937373 DOI: 10.1016/j.purol.2015.03.007] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2015] [Revised: 03/03/2015] [Accepted: 03/24/2015] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Radical prostatectomy (RP) is an oncologic and functional challenge. Few series compare prospectively the two approaches, open retropubic (ORP) and laparoscopic robot-assisted RP (LRARP). The objective was to compare the oncological and functional results of ORP and LRARP. MATERIAL AND METHODS From January 2009 to March 2012, two practiced surgeons conducted 304 consecutive RP: respectively 129 ORP and 175 LRARP. Preoperative, perioperative and postoperative data (location and size of positive surgical margins [PSM]) were recorded prospectively and compared with oncological results (PSM, biochemical recurrence-free survival [BCR]) and functional outcomes (urinary and erectile) by self-validated questionnaires (USP, IIEF-15). The comparison was made by the Chi(2) test and Student t-test for qualitative and quantitative variables. RESULTS The preoperative data 2 groups were comparable. MCP rate was 13.2% for the ORP and 20% for the LRARP (ns) and was 1.4% and 29.6% (ORP) versus 9.4% and 36.7% (LRARP) for pT2 and pT3 for respectively (P=0.078). BCR was the same in both groups (95.2% at 13.1 months). At 12 months, the results of continence showed no difference (P=0.49) and about erectile function, the EF-score was significantly higher in LRARP: 22 versus 17 for the ORP (P=0.03). CONCLUSION Oncological results were comparable after ORP and LRARP. The recovery of continence was excellent regardless of the surgical technique, the recovery of erectile function a bit faster by LRARP. LEVEL OF EVIDENCE 3.
Collapse
Affiliation(s)
- J-B Beauval
- Département d'urologie, andrologie et transplantation rénale, CHU Rangueil, 1, avenue Jean-Pouilhès, 31059 Toulouse cedex, France.
| | - M Roumiguié
- Département d'urologie, andrologie et transplantation rénale, CHU Rangueil, 1, avenue Jean-Pouilhès, 31059 Toulouse cedex, France
| | - M Ouali
- Département d'études statistiques, IUC Oncopôle, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France
| | - N Doumerc
- Département d'urologie, andrologie et transplantation rénale, CHU Rangueil, 1, avenue Jean-Pouilhès, 31059 Toulouse cedex, France
| | - M Thoulouzan
- Département d'urologie, andrologie et transplantation rénale, CHU Rangueil, 1, avenue Jean-Pouilhès, 31059 Toulouse cedex, France
| | - C Mazerolles
- Département d'anatomopathologie, IUC Oncopôle, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France
| | - P Rischmann
- Département d'urologie, andrologie et transplantation rénale, CHU Rangueil, 1, avenue Jean-Pouilhès, 31059 Toulouse cedex, France
| | - B Malavaud
- Département d'urologie, andrologie et transplantation rénale, CHU Rangueil, 1, avenue Jean-Pouilhès, 31059 Toulouse cedex, France
| | - M Soulié
- Département d'urologie, andrologie et transplantation rénale, CHU Rangueil, 1, avenue Jean-Pouilhès, 31059 Toulouse cedex, France
| |
Collapse
|
15
|
Falk AT, Moureau-Zabotto L, Ouali M, Penel N, Italiano A, Bay JO, Olivier T, Sunyach MP, Boudou-Roquette P, Salas S, Le Maignan C, Ducassou A, Isambert N, Kalbacher E, Pan C, Saada E, Bertucci F, Thyss A, Thariat J. Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. Clin Oncol (R Coll Radiol) 2015; 27:48-55. [PMID: 25300878 DOI: 10.1016/j.clon.2014.09.010] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2014] [Revised: 07/31/2014] [Accepted: 09/04/2014] [Indexed: 01/08/2023]
Abstract
AIMS Recent data suggest that patients with pulmonary metastases from sarcomas might benefit from ablation of their metastases. Some data are available regarding osteosarcomas/angiosarcomas and lung metastases. The purpose of this study was to assess the efficacy of local ablative treatment on the survival of patients with oligometastases (one to five lesions, any metastatic site, any grade/histology) from sarcomas. MATERIALS AND METHODS A multicentric retrospective study of the French Sarcoma Group was conducted in sarcoma patients with oligometastases who were treated between 2000 and 2012. Survival was analysed using multivariate sensitivity analyses with propensity scores to limit bias. RESULTS Of the 281 patients evaluated, 164 patients received local treatment for oligometastases between 2000 and 2012. The groups' characteristics were similar in terms of tumour size and remission of the primary tumours. The median follow-up was 25.7 months; 129 (45.9%) patients had died at this point. The median overall survivals were 45.3 (95% confidence interval = 34-73) months for the local treatment group and 12.6 for the other group (95% confidence interval = 9.33-22.9). Survival was better among patients who received local treatment (hazard ratio = 0.47; 95% confidence interval = 0.29-0.78; P < 0.001). Subgroup analyses revealed similar findings in the patients with single oligometastases (hazard ratio = 0.48; 95% confidence interval = 0.28-0.82; P = 0.007); a significant benefit was observed for grade 3, and a trend was observed for grade 2. CONCLUSION Local ablative treatment seemed to improve the overall survival of the patients who presented with oligometastatic sarcomas, including soft tissue and bone sarcomas. The survival benefit remained after repeated local treatments for several oligometastatic events. Surgery yielded the most relevant results, but alternative approaches (i.e. radiofrequency ablation and radiotherapy) seemed to be promising. The relevance of these results is strengthened by our analysis, which avoided biases by restricting the population to patients with oligometastatic disease and used propensity scores.
Collapse
Affiliation(s)
- A T Falk
- Centre Antoine Lacassagne, Nice, France
| | | | - M Ouali
- Centre Claudius Regaud, Toulouse, France
| | - N Penel
- Centre Oscar Lambret, Lille, France
| | | | - J-O Bay
- Centre Jean Perrin, Clermont Ferrand, France; Centre Hospitalier Universitaire Clermont-Ferrand, Clermont-Ferrand, France
| | - T Olivier
- Institut régional du cancer de Montpellier, Montpellier, France
| | | | | | - S Salas
- Paris Descartes University, Paris, France
| | | | | | - N Isambert
- Centre Georges-François Leclerc, Dijon, France
| | - E Kalbacher
- Centre Hospitalier Universitaire, Besançon, France
| | - C Pan
- CHU Henri Mondor, Creteil, France
| | - E Saada
- Centre Antoine Lacassagne, Nice, France
| | - F Bertucci
- Institut Paoli-Calmettes, Marseille, France
| | - A Thyss
- Centre Antoine Lacassagne, Nice, France
| | - J Thariat
- Centre Antoine Lacassagne, Nice, France.
| | | |
Collapse
|
16
|
Le Cesne A, Ouali M, Leahy M, Santoro A, Hoekstra H, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward W, Gronchi A, Hogendoorn P, Litiere S, Marreaud S, Blay J, Van Der Graaf W. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol 2014; 25:2425-2432. [DOI: 10.1093/annonc/mdu460] [Citation(s) in RCA: 114] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litière S, Bonnetain F, Dabakuyo TS, Benjamin RS, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le Péchoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gourgou-Bourgade S, Mathoulin-Pélissier S. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†. Ann Oncol 2014; 26:865-872. [PMID: 25070543 DOI: 10.1093/annonc/mdu360] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2014] [Accepted: 07/23/2014] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-event (TTE) end points is rarely precise and lacks uniformity across trials. End point definition can impact trial results by affecting estimation of treatment effect and statistical power. The DATECAN initiative (Definition for the Assessment of Time-to-event End points in CANcer trials) aims to provide recommendations for definitions of TTE end points. We report guidelines for RCT in sarcomas and gastrointestinal stromal tumors (GIST). METHODS We first carried out a literature review to identify TTE end points (primary or secondary) reported in publications of RCT. An international multidisciplinary panel of experts proposed recommendations for the definitions of these end points. Recommendations were developed through a validated consensus method formalizing the degree of agreement among experts. RESULTS Recommended guidelines for the definition of TTE end points commonly used in RCT for sarcomas and GIST are provided for adjuvant and metastatic settings, including DFS, TTF, time to progression and others. CONCLUSION Use of standardized definitions should facilitate comparison of trials' results, and improve the quality of trial design and reporting. These guidelines could be of particular interest to research scientists involved in the design, conduct, reporting or assessment of RCT such as investigators, statisticians, reviewers, editors or regulatory authorities.
Collapse
Affiliation(s)
- C A Bellera
- Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Centre, Bordeaux; Clinical Epidemiology Unit, INSERM CIC 14.01 (Clinical Epidemiology), Bordeaux.
| | - N Penel
- Department of Medical Oncology, Centre Oscar Lambret, Comprehensive Cancer Centre, Lille, France
| | - M Ouali
- Department of Biostatistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Biostatistics Unit, Institut Claudius Regaud, Comprehensive Cancer Centre, Toulouse
| | - S Bonvalot
- Department of Surgery, Institut Gustave Roussy, Comprehensive Cancer Centre, Villejuif, France
| | - P G Casali
- Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - O S Nielsen
- Faculty of Health Sciences, Aarhus University, Aarhus, Denmark
| | - M Delannes
- Department of Radiotherapy, Institut Claudius Régaud, Comprehensive Cancer Center, Toulouse
| | - S Litière
- Department of Biostatistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium
| | - F Bonnetain
- Methodological and Quality of Life Unit in Oncology (EA3181), CHU Besançon, Besançon
| | - T S Dabakuyo
- Biostatistics and Quality of Life Unit (EA4184), Centre Georges-François Leclerc, Comprehensive Cancer Centre, Dijon, France
| | - R S Benjamin
- Division of Cancer Medicine and Sarcoma Center, The University of Texas M.D. Anderson Cancer Center, Houston, USA
| | - J-Y Blay
- Department of Medical Oncology, Centre Léon Bérard, Comprehensive Cancer Centre, Lyon; Claude Bernard Lyon I University, Lyon; Medical Oncology Unit, Edouard Herriot Hospital, Lyon
| | - B N Bui
- Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux
| | - F Collin
- Department of Biology and Pathology, Centre Georges-François Leclerc, Comprehensive Cancer Centre, Dijon, France
| | - T F Delaney
- Department of Radiation Oncology and Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, USA
| | - F Duffaud
- Department of Medical Oncology, La Timone Hospital University, Marseille, France
| | - T Filleron
- Biostatistics Unit, Institut Claudius Regaud, Comprehensive Cancer Centre, Toulouse
| | - M Fiore
- Department of Surgery and Sarcoma Unit, Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - H Gelderblom
- Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
| | - S George
- Department of Medical Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - R Grimer
- Royal Orthopaedic Hospital NHS Trust, Birmingham, UK
| | - P Grosclaude
- Cancer Registry of Tarn, Institut Claudius Regaud, Comprehensive Cancer Centre, Toulouse, France
| | - A Gronchi
- Department of Surgery and Sarcoma Unit, Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - R Haas
- Department of Radiation Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
| | - P Hohenberger
- Division of Surgical Oncology and Thoracic Surgery, Mannheim University Medical Center, Mannheim
| | - R Issels
- Sarcoma Center, Ludwig-Maximilian University Munich, Munich; Department of Internal Medicine, Klinikum Grosshadern Medical Center, University of Munich, Munich, Germany
| | - A Italiano
- Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux
| | - V Jooste
- Burgundy Digestive Cancer Registry, INSERM U866, University of Burgundy, Dijon, France
| | - A Krarup-Hansen
- Department of Oncology, Herlev Hospital-University Copenhagen, Herlev, Denmark
| | - C Le Péchoux
- Department of Radiotherapy, Institut Gustave Roussy, Comprehensive Cancer Centre, Villejuif, France
| | - C Mussi
- Department of Surgery, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
| | - O Oberlin
- Department of Surgery and Department of Pediatric and Adolescent Oncology, Institut Gustave Roussy, Comprehensive Cancer Centre, Villejuif
| | - S Patel
- Division of Cancer Medicine and Sarcoma Center, The University of Texas M.D. Anderson Cancer Center, Houston, USA
| | - S Piperno-Neumann
- Department of Medical Oncology, Institut Curie, Comprehensive Cancer Centre, Paris, France
| | - C Raut
- Department of Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
| | - I Ray-Coquard
- Department of Medical Oncology, Centre Léon Bérard, Comprehensive Cancer Centre, Lyon
| | - P Rutkowski
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
| | - S Schuetze
- Department of Medical Oncology, University of Michigan, Ann Arbor, USA
| | - S Sleijfer
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
| | - E Stoeckle
- Department of Surgical Oncology, Institut Bergonié, Comprehensive Cancer Centre, Bordeaux, France
| | - M Van Glabbeke
- Department of Biostatistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium
| | - P Woll
- Department of Oncology, Sheffield Cancer Research Centre, Weston Park Hospital, Sheffield, UK
| | - S Gourgou-Bourgade
- Montpellier Cancer Institute, Comprehensive Cancer Centre, Montpellier, France
| | - S Mathoulin-Pélissier
- Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Centre, Bordeaux; Clinical Epidemiology Unit, INSERM CIC 14.01 (Clinical Epidemiology), Bordeaux
| |
Collapse
|
18
|
|
19
|
Gelderblom H, Blay J, Seddon B, Leahy M, Ray-Coquard I, Sleijfer S, Kerst J, Rutkowski P, Bauer S, Ouali M, Marreaud S, van der Straaten R, Guchelaar HJ, Weitman S, Hogendoorn P, Hohenberger P. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. Eur J Cancer 2014; 50:388-96. [DOI: 10.1016/j.ejca.2013.10.002] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2013] [Revised: 09/26/2013] [Accepted: 10/03/2013] [Indexed: 11/29/2022]
|
20
|
Beauval J, Roumiguié M, Ouali M, Doumerc N, Thoulouzan M, Mazerolles C, Rischmann P, Soulié M, Malavaud B. Étude prospective monocentrique comparant une série consécutive de prostatectomies totales rétropubiennes et laparoscopiques robot-assistées : résultats fonctionnels. Prog Urol 2013. [DOI: 10.1016/j.purol.2013.08.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Keus R, Nout R, Blay JY, de Jong J, Hennig I, Saran F, Hartmann J, Sunyach M, Gwyther S, Ouali M, Kirkpatrick A, Poortmans P, Hogendoorn P, van der Graaf W. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis—an EORTC STBSG and ROG study (EORTC 62991–22998). Ann Oncol 2013; 24:2672-2676. [DOI: 10.1093/annonc/mdt254] [Citation(s) in RCA: 106] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
|
22
|
Khalifa J, Boyrie S, Ouali M, Vieillevigne L, Rives M. Comparaison dosimétrique de trois modalités d’irradiation pour le traitement du cancer de la thyroïde non anaplasique : radiothérapie conformationnelle avec modulation d’intensité statique, arcthérapie volumétrique modulée et tomothérapie hélicoïdale. Analyse rétrospective. Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.07.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
23
|
Collette L, Bogaerts J, Suciu S, Fortpied C, Gorlia T, Coens C, Mauer M, Hasan B, Collette S, Ouali M, Litière S, Rapion J, Sylvester R. Statistical methodology for personalized medicine: New developments at EORTC Headquarters since the turn of the 21st Century. EJC Suppl 2012. [DOI: 10.1016/s1359-6349(12)70005-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
24
|
Van Der Graaf WT, Blay J, Chawla SP, Kim D, Bui Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji M, Dei Tos AP, Hohenberger P. PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG Global Network Study (EORTC 62072). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.lba10002] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
LBA10002 Background: Pazopanib, a multi targeted angiogenesis inhibitor, has demonstrated single-agent activity in pts with advanced STS. The efficacy and safety of pazopanib versus placebo as second or later line treatment were evaluated in pts with metastatic STS in a multi-center, international, double-blind, placebo-controlled phase III trial. Methods: Pts ≥18 years of age with angiogenesis inhibitor-naïve, histologically proven, metastatic STS, who failed at least one anthracycline containing regimen, could enter the study. They should have ≥1 measurable baseline lesion (per RECIST v1.0), WHO PS 0-1, adequate bone marrow, coagulation, hepatic and renal function, no poorly controlled hypertension, no bleeding diathesis, and no CNS involvement. The study has been conducted by EORTC and GSK in collaboration with 72 sarcoma centers worldwide. Pts were randomized 2:1 to receive either pazopanib 800 mg once daily or placebo until tumor progression, unacceptable toxicity, death, or pt’s request. Results: A total of 369 randomized pts (246 pazopanib, 123 placebo), median age of 56 years, participated in the study (EORTC 45 %, other 55%). Median duration of follow-up at clinical cut-off date is 15 months. The primary endpoint of progression-free survival (PFS) per independent review is significantly prolonged with pazopanib (median: 20 vs 7 weeks; HR=0.31, 95% CI 0.24-0.40 ; P<0.0001). The interim analysis for overall survival shows a statistically non-significant improvement of pazopanib vs placebo (median: 11.9 vs 10.4 months, HR=0.83, 95% CI 0.62-1.09). Main on-therapy grade 3-4 toxicities in the pazopanib vs placebo arm respectively: fatigue (13%, 6%), hypertension (7%, nil), anorexia (6%, nil), and diarrhea (5%, 1%). Similarly, thromboembolic events (grade 3-5 ) (3%, 2%), LVEF drop of >15% (8%, 3%). Median relative dose intensity of pazopanib was 768 mg daily. Conclusions: Pazopanib is an active drug in anthracycline pretreated metastatic STS pts with an increase in median PFS of 13 weeks.
Collapse
Affiliation(s)
- W. T. Van Der Graaf
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - J. Blay
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - S. P. Chawla
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - D. Kim
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - B. Bui Nguyen
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - P. G. Casali
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - P. Schöffski
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - M. Aglietta
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - A. P. Staddon
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - Y. Beppu
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - A. Le Cesne
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - H. Gelderblom
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - I. R. Judson
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - N. Araki
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - M. Ouali
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - S. Marreaud
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - R. Hodge
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - M. Dewji
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - A. P. Dei Tos
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| | - P. Hohenberger
- Radboud University Medical Centre, Nijmegen, Netherlands; Centre Léon Bérard, Lyon, France; Sarcoma Oncology Center, Santa Monica, CA; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Institut Bergonié, Bordeaux, France; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium; Medical Oncology, University of Torino, Institute for Cancer Research and Treatment, Candiolo,
| |
Collapse
|
25
|
Penel N, Van Glabbeke M, Marreaud S, Ouali M, Blay J, Hohenberger P. Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol 2011; 22:1266-1272. [DOI: 10.1093/annonc/mdq608] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Penel N, Van Glabbeke MM, Bui Nguyen B, Ouali M, Mathoulin-Pelissier S, Marreaud S, Italiano A, Brouste V, Hogendoorn PCW, Coindre J, Blay J, Hohenberger P. Exploratory analysis of prognostic factors for patients (pts) with advanced soft tissue sarcoma (ASTS) receiving combination chemotherapy: A joined study of the EORTC Soft Tissue and Bone Sarcoma Group and the French Sarcoma Group. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Van Der Graaf WT, Blay J, Chawla SP, Kim D, Bui Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji M, Dei Tos AP, Hohenberger P. PALETTE: A randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG Global Network Study (EORTC 62072). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.lba10002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Kroep JR, Ouali M, Gelderblom H, Le Cesne A, Dekker TJA, Van Glabbeke M, Hogendoorn PCW, Hohenberger P. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol 2010; 22:207-214. [PMID: 20656792 DOI: 10.1093/annonc/mdq338] [Citation(s) in RCA: 130] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND the role of chemotherapy in advanced malignant peripheral nerve sheath tumor (MPNST) is unclear. PATIENTS AND METHODS chemotherapy-naive soft tissue sarcomas (STS) patients treated on 12 pooled nonrandomized and randomized European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials were retrospectively analyzed. Clinical outcomes, overall survival, progression-free survival (PFS) and response were determined for MPNST and other STS histotypes and compared. Additionally, prognostic factors within the MPNST population were defined. Studied cofactors were demographics, sarcoma history, disease extent and chemotherapy regimen. RESULTS after a median follow-up of 4.1 years, 175 MPNST out of 2675 eligible STS patients were analyzed. Outcome was similar for MPNST versus other STS histotypes, with a response rate, median PFS and overall survival of 21% versus 22%, 17 versus 16 weeks and 48 versus 51 weeks, respectively. Performance status was an independent prognostic factor for overall survival. Chemotherapy regimen was an independent prognostic factor for response (P < 0.0001) and PFS (P = 0.009). Compared with standard first-line doxorubicin, the doxorubicin-ifosfamide regimen had the best response, whereas ifosfamide had the worst prognosis. CONCLUSION this series indicates the role of chemotherapy in treatment of advanced MPNST. This first comparison showed similar outcomes for MPNST and other STS histotypes. The apparent superiority of the doxorubicin-ifosfamide regimen justifies further investigations of this combination in randomized trials.
Collapse
Affiliation(s)
- J R Kroep
- Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
| | - M Ouali
- European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium
| | - H Gelderblom
- Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
| | - A Le Cesne
- Department of Medicine, Institute Gustave Roussy, Villejuif, France
| | - T J A Dekker
- Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
| | - M Van Glabbeke
- European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium
| | - P C W Hogendoorn
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
| | - P Hohenberger
- Division of Surgical Oncology and Thoracic Surgery, University Hospital Mannheim, University of Heidelberg, Heidelberg, Germany
| |
Collapse
|
29
|
Kroep JR, Ouali M, Gelderblom H, Le Cesne A, Dekker TJ, Van Glabbeke MM, Hohenberger P, Hogendoorn PC. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histologic soft tissue sarcoma (STS) subtypes and as a prognostic factor for MPNST: An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Damak M, Ouali M. A hardware implementation of distributed incubators' networking and supervision. IJBET 2010. [DOI: 10.1504/ijbet.2010.029659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
31
|
Enneddam H, Cherif Idrissi El Ganouni N, Ouali M, Abouzeid C, Essaadouni L, Essadki O, Ousehal A. Apport de l’IRM dans le neurolupus. (À propos de 12 cas). Rev Med Interne 2009. [DOI: 10.1016/j.revmed.2009.10.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
32
|
Aniba K, Ghannane H, Lmejjati M, Ouali M, Jalal H, Ousehal A, Ait Benali S. [Benign sacrococcygeal teratoma in a child: a case report with a review of the literature]. Arch Pediatr 2009; 16:1467-9. [PMID: 19748243 DOI: 10.1016/j.arcped.2009.07.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2008] [Revised: 09/03/2008] [Accepted: 07/21/2009] [Indexed: 11/18/2022]
Abstract
Sacrococcygeal teratomas are rare congenital tumors, generally discovered at birth. These tumors are seldom observed in children. Radical resection must be performed to avoid potentially malignant recurrence even if the primary lesion is benign. We report a case in an 8-year-old girl who did not have a past medical history. Since the age of 2 years, she presented a progressive sacral tumefaction with no neurological deficit. The MRI showed a large sacrococcygeal cyst in hypointense-signal T1-weighted imaging with no contrast enhancement, and a hyperintense signal in T2-weighted imaging. At surgery, the tumor was totally removed. The intraoperative aspect was that of a viscous cyst. The histological study showed a sacrococcygeal teratoma.
Collapse
Affiliation(s)
- K Aniba
- Service de neurochirurgie, CHU Mohamed VI, poste Allal El Fassi, Marrakech, Morocco.
| | | | | | | | | | | | | |
Collapse
|
33
|
Kasper B, Ouali M, Van Glabbeke M, Blay J, Bramwell VH, Woll PJ, Schöffski P. Prognostic factors in adolescents and young adults (AYA) with high-risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on two pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10573 Background: We conducted a retrospective study pooling data from two clinical trials in high risk STS patients with the objective to compare two different age groups: 15 - 29 years (AYA population) and ≥ 30 years. The aim was to determine prognostic factors for the AYA population. Methods: Patients selected for analysis were treated in two randomized trials of adjuvant chemotherapy in STS (EORTC 62771 and 62931). A total of 793 patients were included with a median follow-up (FU) of 8.74 years (AYA population: n = 161, median FU 9.46 years; patients ≥ 30 years: n = 632, median FU 8.62 years). Study endpoints were overall survival (OS) and relapse-free survival (RFS). The variables of the multivariate analysis were gender, subtype and grade, tumor size and localization (limb vs. other), absence or presence of local recurrence and treatment (control arm vs. adjuvant chemotherapy). Results: Patients’ characteristics were globally similar with two exceptions, histological subtype (p = 0.0043) and tumor size (p < .0001). The commonest sarcoma subtype in the AYA population was synovial sarcoma (29 %), whereas leiomyosarcoma (18 %), malignant fibrous histiocytoma (MFH, 16 %) and liposarcoma (15 %) were more frequent in patients ≥ 30 years. For OS, independent favorable prognostic factors were low grade and small tumor size for both groups; radical resection and MFH or liposarcoma subtype were factors of favorable prognosis for patients ≥ 30 years only. For RFS, favorable prognostic factors were small tumor size and low grade for both groups; tumor location in the extremities was a factor of favorable prognosis for the AYA population only, whereas radical resection and adjuvant chemotherapy treatment were favorable factors for patients ≥ 30 years only. Conclusions: On the basis of these data, significant differences could be found concerning prognostic factors between the AYA population and older patients. Interestingly, adjuvant chemotherapy was associated with improved RFS only in patients ≥ 30 years. The results may have further implications on the treatment of STS patients in different age groups as well as the design of future clinical trials. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Kasper
- University of Heidelberg, Heidelberg, Germany; EORTC Data Centre, Brussels, Belgium; Centre Léon Bérard, Lyon, France; Tom Baker Cancer Centre, Calgary, AB, Canada; Weston Park Hospital, Sheffield, United Kingdom; University Hospitals Leuven, Leuven, Belgium
| | - M. Ouali
- University of Heidelberg, Heidelberg, Germany; EORTC Data Centre, Brussels, Belgium; Centre Léon Bérard, Lyon, France; Tom Baker Cancer Centre, Calgary, AB, Canada; Weston Park Hospital, Sheffield, United Kingdom; University Hospitals Leuven, Leuven, Belgium
| | - M. Van Glabbeke
- University of Heidelberg, Heidelberg, Germany; EORTC Data Centre, Brussels, Belgium; Centre Léon Bérard, Lyon, France; Tom Baker Cancer Centre, Calgary, AB, Canada; Weston Park Hospital, Sheffield, United Kingdom; University Hospitals Leuven, Leuven, Belgium
| | - J. Blay
- University of Heidelberg, Heidelberg, Germany; EORTC Data Centre, Brussels, Belgium; Centre Léon Bérard, Lyon, France; Tom Baker Cancer Centre, Calgary, AB, Canada; Weston Park Hospital, Sheffield, United Kingdom; University Hospitals Leuven, Leuven, Belgium
| | - V. H. Bramwell
- University of Heidelberg, Heidelberg, Germany; EORTC Data Centre, Brussels, Belgium; Centre Léon Bérard, Lyon, France; Tom Baker Cancer Centre, Calgary, AB, Canada; Weston Park Hospital, Sheffield, United Kingdom; University Hospitals Leuven, Leuven, Belgium
| | - P. J. Woll
- University of Heidelberg, Heidelberg, Germany; EORTC Data Centre, Brussels, Belgium; Centre Léon Bérard, Lyon, France; Tom Baker Cancer Centre, Calgary, AB, Canada; Weston Park Hospital, Sheffield, United Kingdom; University Hospitals Leuven, Leuven, Belgium
| | - P. Schöffski
- University of Heidelberg, Heidelberg, Germany; EORTC Data Centre, Brussels, Belgium; Centre Léon Bérard, Lyon, France; Tom Baker Cancer Centre, Calgary, AB, Canada; Weston Park Hospital, Sheffield, United Kingdom; University Hospitals Leuven, Leuven, Belgium
| |
Collapse
|
34
|
Ouahra MA, Ouali M. Occupation time problems for fractional Brownian motion and some other self-similar processes. Random Operators and Stochastic Equations 2009. [DOI: 10.1515/rose.2009.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
35
|
Sleijfer S, Ouali M, Van Glabbeke M, Krarup-Hansen A, Leahy MG, Rodenhuis S, Le Cesne A, Hogendoorn PC, Verweij J, Blay JY. Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10509] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Abstract
Lower urinary tract involvement is the common manifestation of systemic sclerosis. It may represent a troublesome disturbance affecting the quality of life in systemic sclerosis patients. We report three patients with progressive systemic sclerosis who manifested pathologic abnormalities in the urinary bladder. The first patient manifested a recurrent macroscopic hematuria requiring transfusions. Both other patients developed functional and urodynamic abnormalities. With a review of the literature on this involvement of the bladder in systemic sclerosis we try to more understand urinary symptoms and urodynamics features of vesical involvement in systemic sclerosis patients.
Collapse
Affiliation(s)
- C Oumaya
- Service d'urologie, hôpital Robert-Debré, rue du Général-Koenig, 51092 Reims, France.
| | | | | | | | | |
Collapse
|
37
|
el Khader K, el Ghorfi MH, Ouali M, Ibnattya A, Hachimi M, Lakrissa A. [Spontaneous hematoma of the adrenal glands]. Prog Urol 2001; 11:517-9. [PMID: 11512468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
We report an uncommon case of unilateral spontaneous hematoma of the right adrenal gland in a 22-year old young man. Preoperative diagnosis was made by ultrasonography and CT-scan. A right adrenalectomy was performed. Pathological evaluation showed an isolated hematoma without adrenal abnormalities. The diagnostic and therapeutic aspects are discussed.
Collapse
Affiliation(s)
- K el Khader
- Service d'Urologie B, Hôpital Avicenne, Rabat, Maroc.
| | | | | | | | | | | |
Collapse
|
38
|
el Khader K, Ouali M, Koutani A, Attya AI, Hachimi M, Lakrissa A. [Transitional cell carcinoma on ureteral stump after nephrectomy for pyonephrosis]. Prog Urol 2001; 11:304-6. [PMID: 11400495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
The authors report a case of transitional cell carcinoma of the left ureteral stump in a 66-year old man treated by nephrectomy for pyonephrosis 6 years previously and cystoprostatectomy for bladder tumour 13 years previously. In the light of this case and based on a review of the literature, they essentially discuss the diagnostic and aetiopathogenic problems raised by this disease.
Collapse
Affiliation(s)
- K el Khader
- Service d'Urologie B, Hôpital Avicenne, Rabat, Maroc.
| | | | | | | | | | | |
Collapse
|
39
|
Ouali M, Laboulais C, Leh H, Gill D, Xhuvani E, Zouhiri F, Desmaele D, d'Angelo J, Auclair C, Mouscadet JF, Le Bret M. Tautomers of styrylquinoline derivatives containing a methoxy substituent: computation of their population in aqueous solution and their interaction with RSV integrase catalytic core. Acta Biochim Pol 2001; 47:11-22. [PMID: 10961674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
8-Hydroxy-2-[2-(3-hydroxy-4-methoxyphenyl)ethenyl]-7-quinoline carboxylic acid and 8-hydroxy-2-[2-(3-methoxy-4-hydroxyphenyl)ethenyl]-7-quinoline carboxylic acid inhibit the processing and strand transfer reactions catalyzed by HIV-1 integrase with an IC50 of 2 microM. Some of their spectral properties are briefly reported. Their fluorescence is so weak that it is of no use in an experimental determination of the binding to the protein and we resorted to computer simulation. Both styrylquinoline derivatives, in their monoanionic form, have several dozens of tautomers and each of these forms has four planar rotamers. In this work computer simulations have been performed to determine which tautomer is the most abundant in aqueous solution and which binds to the Rous sarcoma virus (RSV) integrase catalytic core. As the substituents on the quinoline moiety are the same as on salicylic acid, the energies of hydroxy benzoic acid tautomers were also computed both in vacuo and embedded in a continuous medium which had the dielectric constant of bulk water, using the recent CPCM technique. The CPCM method was then applied to the two integrase inhibitors to estimate the tautomer population in water. The binding site of the compounds on the RSV integrase catalytic core was determined through a docking protocol, consisting of coupling a grid search method with full energy minimization. The designed method is a way leading to identification of potent integrase inhibitors using in silico experiments.
Collapse
Affiliation(s)
- M Ouali
- Laboratoire de Physicochimie et de Pharmacologie des Macromolecules Biologiques, CNRS UMR 8532, LBPA, Ecole Normale Supérieure de Cachan, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
el Khader K, Ouali M, Nouri M, Koutani A, Hachimi M, Lakrissa A. [Urethral diverticulosis in women. Analysis of 15 cases]. Prog Urol 2001; 11:97-102. [PMID: 11296658] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
OBJECTIVE To evaluate the aetiopathogenic, diagnostic and therapeutic aspects of urethral diverticula in women. MATERIAL AND METHODS Over a 10-year period (January 1990 to December 1999), 15 patients with a mean age of 36 years (range: 25 to 46 years) with urethral diverticulum were included in this study. The mean parity was 2 with a history of long and difficult delivery in 6 cases. All patients presented lower urinary tract symptoms with a clinical diverticulum on gynaecological examination (14 cases) or on retrograde and voiding cystourethrography (14 cases) or intravenous urography (one case). Diverticulectomy was performed via a transvaginal approach in the dorsal position. RESULTS There were no postoperative complications. All patients were reviewed with a mean follow-up of 3 years. The urinary symptoms had completely disappeared in 14 cases. One patient was reoperated for recurrent diverticulum. CONCLUSION Young women with recurrent voiding disorders must be examined for the presence of urethral diverticulum that can be confirmed by cystourethrography. Transvaginal diverticulectomy in the lithotomy position is the operation which ensures the best results.
Collapse
Affiliation(s)
- K el Khader
- Service d'Urologie B, Hôpital Avicenne, Rabat, Maroc.
| | | | | | | | | | | |
Collapse
|
41
|
el Khader K, Ouali M, Mahassini N, Ibn Attya A, Hachimi M, Lakrissa A. [Unusual testicular tumor: Leydig, Sertoli, and granulosa cell mixed tumor]. Prog Urol 2001; 11:82-5. [PMID: 11296654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
We report an unusual case of a mixed granulosa-Sertoli-Leydig cell testicular tumor in a 16 year old man, who presented with bilateral gynaecomastia. A few cases have been published in the literature. Based on a case report, the authors describe the clinical, histopathological and therapeutical features of this rare affection.
Collapse
Affiliation(s)
- K el Khader
- Service d'Urologie B, Hôpital Avicenne, Rabat, Maroc.
| | | | | | | | | | | |
Collapse
|
42
|
Abstract
We describe a new classifier for protein secondary structure prediction that is formed by cascading together different types of classifiers using neural networks and linear discrimination. The new classifier achieves an accuracy of 76.7% (assessed by a rigorous full Jack-knife procedure) on a new nonredundant dataset of 496 nonhomologous sequences (obtained from G.J. Barton and J.A. Cuff). This database was especially designed to train and test protein secondary structure prediction methods, and it uses a more stringent definition of homologous sequence than in previous studies. We show that it is possible to design classifiers that can highly discriminate the three classes (H, E, C) with an accuracy of up to 78% for beta-strands, using only a local window and resampling techniques. This indicates that the importance of long-range interactions for the prediction of beta-strands has been probably previously overestimated.
Collapse
Affiliation(s)
- M Ouali
- Department of Computer Science, University of Wales, Ceredigion, United Kingdom.
| | | |
Collapse
|
43
|
Ouali M, Laboulais C, Leh H, Gill D, Desmaële D, Mekouar K, Zouhiri F, d'Angelo J, Auclair C, Mouscadet JF, Le Bret M. Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives. J Med Chem 2000; 43:1949-57. [PMID: 10821707 DOI: 10.1021/jm9911581] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Styrylquinoline derivatives, known to be potent inhibitors of HIV-1 integrase, have been experimentally tested for their inhibitory effect on the disintegration reaction catalyzed by catalytic cores of HIV-1 and Rous sarcoma virus (RSV) integrases. A modified docking protocol, consisting of coupling a grid search method with full energy minimization, has been specially designed to study the interaction between the inhibitors and the integrases. The inhibitors consist of two moieties that have hydroxyl and/or carboxyl substituents: the first moiety is either benzene, phenol, catechol, resorcinol, or salicycilic acid; the hydroxyl substituents on the second (quinoline) moiety may be in the keto or in the enol forms. Several tautomeric forms of the drugs have been docked to the crystallographic structure of the RSV catalytic core. The computed binding energy of the keto forms correlates best with the measured inhibitory effect. The docking procedure shows that the inhibitors bind closely to the crystallographic catalytic Mg(2+) dication. Additional quantum chemistry computations show that there is no direct correlation between the binding energy of the drugs with the Mg(2+) dication and their in vitro inhibitory effect. The designed method is a leading way for identification of potent integrase inhibitors using in silico experiments.
Collapse
Affiliation(s)
- M Ouali
- Laboratoire de Physicochimie et de Pharmacologie des Macromolécules Biologiques, CNRS UMR 8532, LBPA, Ecole Normale Supérieure de Cachan, 61 avenue du Président Wilson, 94235 Cachan, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Ouali M, Laboulais C, Leh H, Gill D, Xhuvani E, Zouhiri F, Desmaele D, D'Angelo J, Auclair C, Mouscadet JF, Le Bret M. Tautomers of styrylquinoline derivatives containing a methoxy substituent: computation of their population in aqueous solution and their interaction with RSV integrase catalytic core. Acta Biochim Pol 2000. [DOI: 10.18388/abp.2000_4058] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
8-Hydroxy-2-[2-(3-hydroxy-4-methoxyphenyl)ethenyl]-7-quinoline carboxylic acid and 8-hydroxy-2-[2-(3-methoxy-4-hydroxyphenyl)ethenyl]-7-quinoline carboxylic acid inhibit the processing and strand transfer reactions catalyzed by HIV-1 integrase with an IC50 of 2 microM. Some of their spectral properties are briefly reported. Their fluorescence is so weak that it is of no use in an experimental determination of the binding to the protein and we resorted to computer simulation. Both styrylquinoline derivatives, in their monoanionic form, have several dozens of tautomers and each of these forms has four planar rotamers. In this work computer simulations have been performed to determine which tautomer is the most abundant in aqueous solution and which binds to the Rous sarcoma virus (RSV) integrase catalytic core. As the substituents on the quinoline moiety are the same as on salicylic acid, the energies of hydroxy benzoic acid tautomers were also computed both in vacuo and embedded in a continuous medium which had the dielectric constant of bulk water, using the recent CPCM technique. The CPCM method was then applied to the two integrase inhibitors to estimate the tautomer population in water. The binding site of the compounds on the RSV integrase catalytic core was determined through a docking protocol, consisting of coupling a grid search method with full energy minimization. The designed method is a way leading to identification of potent integrase inhibitors using in silico experiments.
Collapse
|
45
|
Abstract
We have compared the accuracy of the individual protein secondary structure prediction methods: PHD, DSC, NNSSP and Predator against the accuracy obtained by combing the predictions of the methods. A range of ways of combing predictions were tested: voting, biased voting, linear discrimination, neural networks and decision trees. The combined methods that involve 'learning' (the non-voting methods) were trained using a set of 496 non-homologous domains; this dataset was biased as some of the secondary structure prediction methods had used them for training. We used two independent test sets to compare predictions: the first consisted of 17 non-homologous domains from CASP3 (Third Community Wide Experiment on the Critical Assessment of Techniques for Protein Structure Prediction); the second set consisted of 405 domains that were selected in the same way as the training set, and were non-homologous to each other and the training set. On both test datasets the most accurate individual method was NNSSP, then PHD, DSC and the least accurate was Predator; however, it was not possible to conclusively show a significant difference between the individual methods. Comparing the accuracy of the single methods with that obtained by combing predictions it was found that it was better to use a combination of predictions. On both test datasets it was possible to obtain a approximately 3% improvement in accuracy by combing predictions. In most cases the combined methods were statistically significantly better (at P = 0.05 on the CASP3 test set, and P = 0.01 on the EBI test set). On the CASP3 test dataset there was no significant difference in accuracy between any of the combined method of prediction: on the EBI test dataset, linear discrimination and neural networks significantly outperformed voting techniques. We conclude that it is better to combine predictions.
Collapse
Affiliation(s)
- R D King
- Department of Computer Science, University of Wales, Aberystwyth Penglais, Aberystwyth, Ceredigion, SY23 3DB, Wales, UK
| | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
In this work we selected double-stranded DNA sequences capable of forming stable triplexes at 20 or 50 degrees C with corresponding 13mer purine oligonucleotides. This selection was obtained by a double aptamer approach where both the starting sequences of the oligonucleotides and the target DNA duplex were random. The results of selection were confirmed by a cold exchange method and the influence of the position of a 'mismatch' on the stability of the triplex was documented in several cases. The selected sequences obey two rules: (i) they have a high G content; (ii) for a given G content the stability of the resulting triplex is higher if the G residues lie in stretches. The computer simulation of the Mg2+, Na+and Cl-environment around three triplexes by a density scaled Monte Carlo method provides an interpretation of the experimental observations. The Mg2+cations are statistically close to the G N7 and relatively far from the A N7. The presence of an A repels the Mg2+from adjacent G residues. Therefore, the triplexes are stabilized when the Mg2+can form a continuous spine on G N7.
Collapse
Affiliation(s)
- A Debin
- CNRS UMR 8532, Institut Gustave-Roussy, 94805 Villejuif, France
| | | | | | | | | | | |
Collapse
|
47
|
Storme L, Ouali M, Ganga-Zandzou PS, Klosowski S, Rakza T, Fassler C, Haouari N, Kacet N, Lequien P. [Use of double-lumen umbilical vein catheters in a neonatal intensive care unit]. Arch Pediatr 1999; 6:386-90. [PMID: 10230477 DOI: 10.1016/s0929-693x(99)80219-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The aim of the study was to compare the success/failure rate and complications of insertion into the umbilical vein, of either double-lumen catheters (Charrière diameter 04, length 13 and 30 cm) or single-lumen catheters (Charrière diameter 05, length 40 cm) in a population of neonates admitted to a neonatal intensive care unit. The numbers of insertions of additional peripheral venous catheters were also compared. PATIENTS AND METHODS The population was divided into two groups according to the severity of the respiratory failure. Group 1 (n = 52): normal hemodynamic parameters and moderate respiratory failure (FiO2 < 0.6): only single-lumen catheters were used. Group 2 (n = 56): low systemic pressure requiring vascular filling and/or inotropic drugs infusion and/or severe respiratory failure (FiO2 > 0.6): in this group, either single-lumen catheters or double-lumen catheters were inserted. RESULTS The success rate of insertion of double-lumen catheters and of single-lumen catheters were similar (61% vs 71%: P = 0.7). Nineteen double-lumen catheters were inserted in the group 2. The average duration of double-lumen umbilical catheterization was not significantly different from simple-lumen catheterization (4.9 +/- 2.2 vs 4.6 +/- 2.2 days). Complications relating to the umbilical venous catheterization were uncommon: three catheter obstructions (two with single-lumen catheter, one with double-lumen catheters), two nosocomial infections (both with single-lumen catheter), one hydropericardium (with single-lumen catheter). In group 2, more peripheral venous catheters were required during the first 72 hours of life after insertion of single-lumen catheter than after insertion of double-lumen catheters (average number of peripheral venous catheters per infant: 1.6 +/- 0.83 vs 1 +/- 0.35 respectively; P < 0.01). CONCLUSION Feasibility and complication rate of umbilical double-lumen catheters were similar to those of single-lumen catheters. The use of umbilical double-lumen catheters reduces the need of peripheral venous catheters.
Collapse
Affiliation(s)
- L Storme
- Service de médecine néonatale, hôpital Jeanne-de-Flandre, CHRU, Lille, France
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Michaud L, Gottrand F, Ganga-Zandzou PS, Ouali M, Vetter-Laffargue A, Lambilliotte A, Dalmas S, Turck D. Nitrous oxide sedation in pediatric patients undergoing gastrointestinal endoscopy. J Pediatr Gastroenterol Nutr 1999; 28:310-4. [PMID: 10067734 DOI: 10.1097/00005176-199903000-00018] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
BACKGROUND The ideal medication to administer to children before gastrointestinal endoscopy procedures has yet to be found. The efficacy of using inhaled nitrous oxide during endoscopy in children was assessed in a pilot study. METHODS Patients aged 5 to 17 years, referred to our hospital for diagnostic upper gastrointestinal endoscopy or rectosigmoidoscopy procedures, were eligible for enrollment in this study. All received 50% nitrous oxide in oxygen (Entonox; AGA, Rueil-Malmaison, France) before endoscopy and some of them again during endoscopy. The pediatric endoscopist and the nurse performing the procedure were separately asked to rate cooperation, emotional state, drowsiness and overall efficacy of sedation. Oxygen saturation and adverse effects were recorded throughout the procedure. After endoscopy, children scored their degree of pain during the procedures on a visual analog scale (0, no pain; 100, agony) and on a body outline (projective method). Any adverse effects were noted. RESULTS Thirty-seven patients were enrolled in the study. Thirty patients underwent diagnostic upper gastrointestinal endoscopy and seven diagnostic rectosigmoidoscopy. The median time from administration of nitrous oxide until insertion of the endoscope was 5 minutes (range, 3-8 minutes). Good or excellent efficacy of the sedation was noted in 92% of children by the endoscopist and in 89% by the nurses. Good or excellent cooperation was noted in 92% of the children by the endoscopist and in 78% by the nurses. The children's pain score on the visual analog scale ranged from 5 to 100 (median, 20) for upper gastrointestinal endoscopy and from 0 to 30 (median, 0) for rectosigmoidoscopy. The time of discharge after endoscopy, defined as the time elapsed between the end of the endoscopy and discharge from the endoscopy suite, varied from 1 to 7 minutes (median, 1.5 minutes). CONCLUSION Entonox provides rapid and effective analgesia without heavy sedation, leads to adequate relaxation and cooperation, and facilitates quick and efficient endoscopy. The effect of Entonox was of short duration, allowing the children to leave the endoscopy unit without need for a long recovery period. The adverse effects of Entonox appeared to be minor, and their duration was always brief. Nitrous oxide-oxygen inhalation may provide a valuable alternative to conventional sedation regimens during gastrointestinal endoscopy in children, but randomized and prospective studies comparing nitrous oxide sedation and conventional sedation regimens are necessary.
Collapse
Affiliation(s)
- L Michaud
- Department of Pediatric Gastroenterology, Lille University Hospital, France
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Michaud L, Gottrand F, Ouali M, Ganga-Zandzou SP, Lambilliotte A, Vetter-Laffargue A, Dalmas S, Turck D. Sédation par protoxyde d'azote inhalé en endoscopie digestive haute chez l'enfant. Arch Pediatr 1998. [DOI: 10.1016/s0929-693x(97)86910-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
50
|
Ouali M, Gousset H, Geinguenaud F, Liquier J, Gabarro-Arpa J, Le Bret M, Taillandier E. Hydration of the dTn.dAn x dTn parallel triple helix: a Fourier transform infrared and gravimetric study correlated with molecular dynamics simulations. Nucleic Acids Res 1997; 25:4816-24. [PMID: 9365262 PMCID: PMC147119 DOI: 10.1093/nar/25.23.4816] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
We present a comparative analysis of the water organization around the dTn.dAn x dTn triple helix and the Watson-Crick double helix dTn.dAn respectively by means of gravimetric measurements, infrared spectroscopy and molecular dynamics simulations. The hydration per nucleotide determined by gravimetric and spectroscopic methods correlated with the molecular dynamics simulations shows that at high relative humidity (98% RH) the triple helix is less solvated than the duplex (17 +/- 2 water molecules per nucleotide instead of 21 +/-1). The experimental desorption curves are different for both structures and indicate that below 81% RH the triplex becomes more hydrated than the duplex. At this RH the FTIR spectra show the emergence of N-type sugars in the adenosine strand of the triplex. When the third strand is bound in the major groove of the Watson-Crick duplex molecular dynamics simulations show the formation of a spine of water molecules between the two thymidine strands.
Collapse
Affiliation(s)
- M Ouali
- Laboratoire CSSB, URA CNRS 1430, UFR Santé Médecine et Biologie Humaine, Université Paris XIII, 74 rue Marcel Cachin, 93017 Bobigny, France
| | | | | | | | | | | | | |
Collapse
|